FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Eversource 2026年第一季度:强劲的运营业绩被FERC输电收益下降所抵消

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:Eversource公布了2026年第一季度业绩,非GAAP每股收益为1.73美元(同比增长0.23美元),营收增长9.4%至45亿美元,但GAAP每股收益1.61美元包含0.12美元的联邦能源监管委员会(FERC)相关费用。天然气分销业务盈利2.953亿美元(同比增长35.2%),主要得益于2025年11月的价格上涨;电力输配业务尽管面临挑战,仍保持稳定增长。FERC的决定将输电业务的净资产收益率(ROE)从10.57%下调至9.57%,导致Eversource将2026年每股收益预期从4.80-4.95美元下调至4.57-4.72美元,首席执行官Joe Nolan称该决定“武断且有缺陷”。尽管面临短期挑战,Eversource 仍维持其长期每股收益复合年增长率 (EPS CAGR) 预期,即到 2030 年实现 5%-7% 的增长,并以 2026 年调整后的中值 4.65 美元作为基准年。我们认为,该公司预计到 2028 年,年盈利增长将接近其预期范围的上半部分,这表明该公司有信心在应对挑战的同时,继续进行基础设施投资。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661